Almirall, S.A. (ALM.MC) and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top-line results of ATTAIN, a six month double-blind placebo-controlled pivotal Phase III study comparing the efficacy and safety of inhaled aclidinium bromide 200μg and 400μg twice daily (BID) versus placebo, in 828 patients with moderate to severe COPD.

Aclidinium 200µg and 400µg produced statistically significant increases from baseline in morning pre-dose (trough) FEV1 versus placebo at week 24 (99mL and 128mL, respectively; p

Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Forest Road Acquisition Charts.
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Forest Road Acquisition Charts.